CD226+ B cells in primary Sjögren’s syndrome: a key player in clinical manifestations and disease pathogenesis
CD226<sup>+</sup> B cells are expanded in pSS, strongly correlating with clinical manifestations and disease activity. These cells display enhanced effector profiles (activation, cytokine/immunoglobulin production) and demonstrate diagnostic utility. Our findings identify CD226<sup>+</sup> B cell as a pathogenic driver in pSS, positioning CD226 as a promising novel therapeutic target and biomarker.
Authors
- Xin Chang (ORCID: https://orcid.org/0009-0003-2863-6019)
- Changhao Xie (ORCID: https://orcid.org/0000-0001-5039-5969)
- Zhongli Hu (ORCID: https://orcid.org/0009-0004-7587-3380)
- Cheng Peng (ORCID: https://orcid.org/0000-0003-2629-9437)
- Song Zhang (ORCID: https://orcid.org/0000-0002-1263-6693)
- Wei Cheng (ORCID: https://orcid.org/0009-0008-8350-5202)
- Cuiping Liu (ORCID: https://orcid.org/0000-0002-7383-1505)
- Ping Zhao
- Saizhe Song
Institutions
- Bengbu Medical College (CN)
- Soochow University (CN)
- Changshu No.1 People's Hospital (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-25
- DOI
- https://doi.org/10.3389/fimmu.2025.1623774
- Citations
- 2
- Primary Topic
- Salivary Gland Disorders and Functions
- Type
- article
- Field-Weighted Citation Impact
- 2.33